pharma · Endometrial cancer · Specific Advanced Solid Tumors · ACRV
Acrivon Therapeutics
Acrivon Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ACRV. Primary therapeutic focus areas include Endometrial cancer, Specific Advanced Solid Tumors, Endometrial
Cambridge, USA HQ
2018 Founded
84 Employees
Public company Type
ACRV · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2018
- Employees
- 84
- Programs
- 4
- Drugs
- 3
- Patents
- 0
Gemcitabine
Phase 2 · small molecule · Head and Neck Squamous Cell Carcinoma
Gemcitabine for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Acrivon Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MCC-22485
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Acrivon Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Head and Neck Squamous Cell Carcinoma
- Status
- active
- Trials
- 1